Incidence and predictive factors for malignancies with dermatomyositis: A cohort from southern China

Clinical and Experimental Rheumatology

Volumn 32, Issue 5, 2014, Pages 615-621

  Chen, Dongying ^a   Yuan, Shiwen ^a   Wu, Xiangni ^a   Li, Hao ^a   Qiu, Qian ^a   Zhan, Zhongping ^a   Ye, Yujin ^a   Lian, Fan ^a   Liang, Liuqin ^a   Xu, Hanshi ^a   Yang, Xiuyan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Dermatomyositis; Malignancy; Prediction analysis

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SCREENING; CHINA; COHORT ANALYSIS; COLON CARCINOMA; COMORBIDITY; CONTROLLED STUDY; DEATH; DEMOGRAPHY; DERMATOMYOSITIS; DISEASE DURATION; DYSPHAGIA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GENDER; HUMAN; INTERSTITIAL LUNG DISEASE; LABORATORY TEST; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NASOPHARYNX CARCINOMA; OVARY CARCINOMA; PREDICTION; RETROSPECTIVE STUDY; RISK FACTOR; SYMPTOM; UNIVERSITY HOSPITAL; CHI SQUARE DISTRIBUTION; EARLY DIAGNOSIS; EPIDEMIOLOGY; INCIDENCE; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASMS; PREDICTIVE VALUE; PROGNOSIS; RISK; STATISTICAL MODEL; TIME;

CHI-SQUARE DISTRIBUTION; CHINA; COMORBIDITY; DERMATOMYOSITIS; EARLY DETECTION OF CANCER; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; NEOPLASMS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84907571926     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. TANSLEY SL, McHUGH NJ, WEDDERBURN LR: Adult and juvenile dermatomyositis: are the distinct clinical features explained by our current understanding of serological subgroups and pathogenic mechanism? Arthritis Res Ther 2013; 15: 211
2. BITNUM S, DAESCHNER CW Jr, TRAVIS LB et al.: Dermatomyositis. J Pediatr 1964; 64: 101-31.
3. RAVELLI A, TRAIL L, FERRARI C et al.: Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) 2010; 62: 63-72.
4. DANKÓ K, PONYI A, CONSTANTIN T et al.: Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 2004; 83: 35-42.
5. CHOW WH, GRIDLEY G, MELLEMKJAER L et al.: Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 1995; 6: 9-13.
6. AIRIO A, PUKKALA E, ISOMOKI H et al.: Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 1995; 22: 1300-3.
7. STOCKTON D, DOHERTY VR, BREWSTER DH et al.: Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 2001; 85: 41-5.
8. SIGURGEIRSSON B, LINDELÖF B, EDHAG O et al.: Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 1992; 326: 363-7.
9. BUCHBINDER R, FORBES A, HALL S et al.: Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population based cohort study. Ann Intern Med 2001; 134: 1087-95.
10. CHEN YJ, WU CY, HUANG YL et al.: Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 2010; 12: R70.
11. ROBINSON AB, REED AM: Clinical features, parthenogenesis, and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol 2011; 7: 664-75.
12. FARDET L, DUPUY A, GAIN M et al.: Factors associated underlying malignancy in a retrospective cohort of 121 patients with dermatomyositis. Medicine (Baltimore) 2009; 88: 91-7.
13. ANDRAS C, PONYI A, CONSTANTIN T et al.: Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 2008; 35: 438-44.
14. AMERIO P, GIRARDELLI CR, PROIETTO G et al.: Usefulness of erythrocyte sedimentation rate as tumor marker in cancer associated dermatomyositis. Eur J Dermatol 2002; 12: 165-9.
15. BUCHBINDER R, HILL CL: Malignancy in patients with inflammatory myopathy. Curr Rheumatol Rep 2002; 4: 415-26.
16. MADAN V, CHINOY H, GRIFFITHS CE et al.: Defining cancer risk in dermatomyositis. Part 1. Clin Exp Dermatol 2009; 34: 451-5.
17. UNGPRASERT P, LEEAPHORN N, HOSIRILUCK N et al.: Clinical features of inflammatory myopathies and their association with malignancy: A systematic review in Asian population. ISRN Rheumatol 2013; 2013: 509354.
18. BOHAN A, PETER JB: Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344-7.
19. LINKLATER H, PIPITONE N, ROSE MR et al.: Classifying idiopathic inflammatory myopathies: comparing the performance of six existing criteria. Clin Exp Rheumatol 2013; 31: 767-9.
20. ANSELL BM: Juvenile dermatomyositis. Rheum Dis Clin North Am 1991; 17: 931-42.
21. MORRIS P, DARE J: Juvenile dermatomyo-sitis as a para-neoplastic syndrome: an update. J Pediatr Hematol Oncol 2010; 32: 189-91.
22. AZUMA K, YAMADA H, OHKUBO M et al.: Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis, and clinically amyopathic dermatomyositis. Mod Rheumatol 2011; 21: 178-83.
23. RASKOVIĆ S, BOLPACIĆ J, SPIRIĆ VT et al.: Importance of dysphagia examination in patient with dermatomyositis-case report. Med Pregl 2012; 65: 432-5.
24. ODDIS CV, CONTE CG, STEEN VD et al.: Incidence of polymyositis and dermatomyositis: a 20-year study of hospital diagnosed cases in Allegheny Country, PA 1963-1982. J Rheumatol 1990; 17: 1329-34.
25. VARGAS-LEGUÁS H, SELVA-O'CALLAGHAN A, CAMPINS-MARTÍ M et al.: Polymyositis and dermatomyositis: incidence in Spain (1997-2004). Med Clin (Barc) 2007; 129: 721-4.
26. HILL CL, ZHANG Y, SIGURGEIRSSON B et al.: Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 2001; 357: 96-100.
27. ZANTOS D, ZHANG Y, FELSON D et al.: The overall and temporal association of cancer with polymyositis and dermatomyositis. J Rheumatol 1994; 21:1855-9.
28. PRASAD ML, SARKAR C, ROY S et al.: Idiopathy inflammatory myopathy: clinicopathological observations in the India population. Br J Rheumatol 1992; 31: 835-9.
29. YOSIPOVITCH G, TAN A, LOSICCO K et al.: A comparative study of clinical characteristics, work-up, treatment, and association with malignancy in dermatomyositis between two tertiary skin centers in the USA and Singapore. Int J Dermatol 2013; 52: 813-9.
30. LIMAYE V, LUKE C, TUCKER G et al.: The incidence and association of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol Int 2013; 33: 965-71.
31. ZAHR ZA, BAER AN: Malignancy in myositis. Curr Rheumatol Rep 2011; 13: 208-15.
32. CHEN YJ, WU CY, SHEN JL: Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 2001; 144: 825-31.
33. TADA Y, SUEMATSU E, UEDA A et al.: Clinical factors to predict a poor prognosis and refractory disease in patients with polymyositis and dermatomyositis associated with interstitial lung disease. Clin Exp Rheumatol 2012; 30: 450.
34. ANTIOCHOS BB, BROWN LA, LI Z et al.: Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USA. J Rheumatol 2009; 36: 2704-10.